Ubs Group Ag Next Cure, Inc. Transaction History

Ubs Group Ag

$555 Billion
Q2 2025

A detailed history of Ubs Group Ag transactions in Next Cure, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 12,299 shares of NXTC stock, worth $79,451. This represents 0.0% of its overall portfolio holdings.

Number of Shares

12,299

Previous 8,537 44.07%

Holding current value

$79,451

Previous $4,000 25.0%

% of portfolio

0.0%

Previous 0.0%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$0.27 - $0.68 $1,015 - $2,558	3,762 Added 44.07%	12,299 $5,000
Q1 2025 May 13, 2025	BUY	$0.48 - $0.95 $2,080 - $4,118	4,335 Added 103.17%	8,537 $4,000
Q4 2024 Feb 14, 2025	SELL	$0.77 - $1.54 $973 - $1,946	-1,264 Reduced 23.12%	4,202 $3,000
Q3 2024 Nov 14, 2024	SELL	$1.33 - $1.78 $5,934 - $7,942	-4,462 Reduced 44.94%	5,466 $7,000
Q2 2024 Aug 13, 2024	SELL	$1.17 - $2.49 $1,035 - $2,203	-885 Reduced 8.18%	9,928 $15,000
Q1 2024 May 13, 2024	BUY	$1.13 - $2.23 $5,136 - $10,137	4,546 Added 72.54%	10,813 $24,000
Q4 2023 Feb 09, 2024	SELL	$1.03 - $1.45 $5,592 - $7,873	-5,430 Reduced 46.42%	6,267 $7,000
Q3 2023 Nov 09, 2023	SELL	$1.29 - $1.84 $5,117 - $7,299	-3,967 Reduced 25.33%	11,697 $15,000
Q2 2023 Aug 11, 2023	BUY	$1.47 - $1.86 $4,302 - $5,444	2,927 Added 22.98%	15,664 $28,000
Q1 2023 May 12, 2023	BUY	$1.46 - $1.83 $3,079 - $3,859	2,109 Added 19.84%	12,737 $18,000
Q4 2022 Feb 08, 2023	BUY	$1.2 - $3.07 $781 - $1,998	651 Added 6.53%	10,628 $14,000
Q3 2022 Nov 10, 2022	BUY	$2.72 - $5.19 $1,768 - $3,373	650 Added 6.97%	9,977 $27,000
Q2 2022 Aug 10, 2022	BUY	$3.38 - $5.27 $564 - $880	167 Added 1.82%	9,327 $44,000
Q1 2022 May 16, 2022	BUY	$4.76 - $6.24 $30,168 - $39,549	6,338 Added 224.59%	9,160 $45,000
Q4 2021 Feb 14, 2022	BUY	$5.7 - $9.1 $15,851 - $25,307	2,781 Added 6782.93%	2,822 $17,000
Q3 2021 Nov 15, 2021	BUY	$6.74 - $8.02 $155 - $184	23 Added 127.78%	41 $0
Q2 2021 Aug 13, 2021	SELL	$7.6 - $10.28 $15,982 - $21,618	-2,103 Reduced 99.15%	18 $0
Q1 2021 May 12, 2021	SELL	$9.81 - $13.88 $54,955 - $77,755	-5,602 Reduced 72.54%	2,121 $21,000
Q4 2020 Feb 11, 2021	BUY	$9.47 - $12.43 $72,653 - $95,362	7,672 Added 15043.14%	7,723 $84,000
Q3 2020 Nov 12, 2020	BUY	$8.15 - $21.17 $415 - $1,079	51 New	51 $0
Q2 2020 Jul 31, 2020	SELL	$21.19 - $40.2 $193,952 - $367,950	-9,153 Closed	0 $0
Q1 2020 May 01, 2020	BUY	$32.32 - $58.37 $278,048 - $502,157	8,603 Added 1564.18%	9,153 $339,000
Q4 2019 Feb 14, 2020	SELL	$25.0 - $92.22 $47,300 - $174,480	-1,892 Reduced 77.48%	550 $31,000
Q3 2019 Nov 14, 2019	BUY	$15.73 - $41.6 $15,698 - $41,516	998 Added 69.11%	2,442 $75,000
Q2 2019 Aug 14, 2019	BUY	$14.16 - $20.64 $20,447 - $29,804	1,444 New	1,444 $22,000

Others Institutions Holding NXTC

# of Institutions

Shares Held

10.8M

Call Options Held

Put Options Held

View Full List

About NextCure, Inc.

Ticker NXTC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 27,748,800
Market Cap $179M
Description
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The comp...

More about NXTC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account